Apollo Endosurgery to Participate in Digestive Disease Week® 2019
May 15 2019 - 4:00PM
Business Wire
Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq: APEN), a global
leader in less invasive medical devices for gastrointestinal and
bariatric procedures, announced today its participation during
Digestive Disease Week 2019 (“DDW”). DDW will be held May 18-21,
2019 at the San Diego Convention Center in San Diego,
California.
Apollo’s OverStitch™ Endoscopic Suturing System and ORBERA®
Intragastric Balloon, will be featured in 40 clinical presentations
that demonstrate the effectiveness of OverStitch and ORBERA when
used across a number of diverse clinical needs.
Apollo will also feature Overstitch Sx, its latest endoscopic
suturing device designed for compatibility with single-channel
endoscopes with diameters ranging from 8.8mm to 9.8mm. The
Overstitch Sx provides a greater number of physicians with access
to the benefits of full-thickness flexible endoscopic suturing
regardless of their hospital’s selection of endoscopic capital
equipment or endoscope manufacturer.
In addition, Apollo will unveil Apollo Care, a nutritional and
activity-based patient management platform designed to provide
physicians and dietitians the ability to deliver personalized
weight loss coaching programs to their patients without the need
for frequent in-office visits.
During the conference, DDW will host hands-on workshops for its
attendees including sessions that feature the OverStitch and ORBERA
technologies. In addition, the Apollo Mobile Learning Center will
be in San Diego to support personalized hands-on physician
training. The Apollo Mobile Learning Center is a state-of-the-art
mobile training facility that allows for advanced endoscopic
training programs to be conducted in individual local markets.
About OverStitch™
The OverStitch endoscopic suturing system enables advanced
endoscopic surgery by allowing physicians to place full-thickness
sutures from a flexible endoscope. This new technology enables a
secure approximation of tissue endoscopically and a wide range of
less invasive solutions for physicians who treat defects in both
the upper and lower GI tract of their patients. Additionally,
physicians are leveraging endoscopic suturing to perform a variety
of advanced bariatric procedures. For more information regarding
OverStitch go to: www.overstitch.com.
About ORBERA®
ORBERA® is an incision-less, non-surgical weight loss solution
designed for adult patients suffering from obesity, who are not
appropriate for or considering invasive surgery, but for whom diet
and exercise or pharmaceutical interventions have not worked.
In a non-surgical (endoscopic) procedure, the thin and deflated
ORBERA balloon is placed into the stomach. It is then filled with
saline until it’s about the size of a grapefruit. The procedure
typically takes about 20 to 30 minutes and the patient can
generally go home the same day. At six months, through another
non-surgical procedure, the ORBERA balloon is deflated and then
removed.
Once the balloon is in place, the patient receives an
individually tailored support program through the ORBERA Managed
Weight Loss System team of experts to help keep them motivated,
coordinate their program and help them work through weight loss
barriers to meet their long-term weight loss goals. Coaching takes
place over 12 months, even though the balloon is removed after six
months. The program is designed to help the patient develop
sustainable, healthy habits that will help keep weight off over
time.
For more than 20 years, the global medical community has been
using intragastric balloons from the makers of ORBERA to help
thousands of people lose weight. More than 295,000 ORBERA balloons
have been distributed worldwide in over 70 countries.
For additional information regarding ORBERA, please visit
www.orbera.com.
For full safety information please visit www.orbera.com/dfu,
talk with your doctor, or call Apollo Customer Support at
1-855-MYORBERA.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused
on less invasive therapies to treat various gastrointestinal
conditions, ranging from gastrointestinal defect repairs to the
interventional treatment of obesity. Apollo's device-based
therapies are an alternative to invasive surgical procedures, thus
lowering complication rates and reducing total healthcare costs.
Apollo's products are offered in over 70 countries today and
include the OverStitch™ Endoscopic Suturing System, the OverStitch
Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric
Balloon.
Apollo’s common stock is traded on Nasdaq Global Market under
the symbol "APEN." For more information regarding Apollo, go to:
www.apolloendo.com.
© 2018 Apollo Endosurgery, Inc. All rights reserved. Any
third-party trademarks used herein are the property of their
respective owners.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations.
Important factors that could cause actual results to differ
materially include: the advancement of Apollo products; development
of enhancements to Apollo’s existing products and technologies;
market acceptance of Apollo’s products; the execution of our gross
margin improvement projects; the ability to collect future payments
from ReShape; and statements relating to the availability of cash
for Apollo's future operations; Apollo’s ability to support the
adoption of its products and its ability to broaden its product
portfolio as well as other factors detailed in Apollo’s periodic
reports filed with the Securities and Exchange Commission, or SEC,
including its Form 10-K for the year ended December 31, 2018 and
its Form 10-Q for the three months ended March, 31, 2019. Copies of
reports filed with the SEC are posted on Apollo’s website and are
available from Apollo without charge. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, Apollo
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515005844/en/
Media Contact:Jen Cook, 512-279-5158jen.cook@apolloendo.com
Investor Contacts:John Gillings, 512-279-5100Investor Relations
Managerinvestor-relations@apolloendo.com
Apollo Endosurgery (NASDAQ:APEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apollo Endosurgery (NASDAQ:APEN)
Historical Stock Chart
From Apr 2023 to Apr 2024